India's Pharma Exports Face Disruptions and Losses Amid Middle East Conflict

India's pharmaceutical exports face potential disruptions and financial losses due to the escalating Middle East conflict. Key shipping routes, including the Red Sea and Suez Canal, risk delays and increased transit times, affecting temperature-sensitive medicines. Freight costs have doubled, with surcharges adding pressure on exporters. Markets in the Gulf Cooperation Council and West Asia, significant destinations for Indian generics and vaccines, may experience shipment delays and payment issues. Industry leaders urge government collaboration to mitigate these challenges.